Please login to the form below
Pfizer/BioNTech
This page shows the latest Pfizer/BioNTech news and features for those working in and with pharma, biotech and healthcare.
Pfizer starts RSV trial ahead of winter season
A vaccine against the common respiratory syncytial virus could be available soon, as Pfizer joins GSK and J&J in launching phase 3 trials. ... Harnessing expertise gained from developing vaccines against COVID-19, Moderna has announced it intended to
Latest news
-
FDA experts to evaluate Pfizer-BioNTech COVID-19 booster
The race to approve a third booster shot of Pfizer-BioNTech vaccine may well be a photo finish, as the FDA announces that its expert panel will convene just three days ... On 25 August, Pfizer/BioNTech announced the initiation of a supplemental biologics
-
FDA opens door to COVID-19 booster jabs
The FDA has amended its emergency use authorisations for both approved mRNA vaccines – Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax – for use as a booster/third jab for “certain immunocompromised
-
Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
Pfizer has raised its financial guidance as its BioNTech-partnered COVID-19 vaccine continues to make gains, with the jab bringing in a total of $7.8bn in the second quarter ... Currently, Pfizer and BioNTech are expecting to manufacture up to three
-
Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
of the Pfizer/BioNTech vaccine – both of these induced higher antibodies than two doses of the AZ vaccine. ... first dose of the AstraZeneca/Oxford University vaccine followed by the Pfizer/BioNTech vaccine – provide good protection against COVID-19.
-
One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
Another study, from Public Health England (PHE), found earlier this week that two doses of the AZ vaccine or the Pfizer/BioNTech vaccine could protect against symptoms caused by the Alpha ... In the PHE study, two doses of the Pfizer/BioNTech vaccine
FDA experts to evaluate Pfizer-BioNTech COVID-19 booster
Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
More from news
Approximately 60 fully matching, plus 115 partially matching documents found.
Latest Intelligence
-
Rare genetic diseases – what’s in store for 2021?
In the UK, the looming Brexit sparked new models of regulatory approval and fast-track opportunities, as recently observed in the rapid approval of Pfizer’s COVID-19 vaccine. ... So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University
-
Working together against COVID-19
Beyond the connection between HCPs and pharma or NGOs, it is encouraging to see collaborations such as Clover and GSK evaluating a vaccine candidate and Pfizer and Biontech doing the same. ... A number of top pharma companies are included in the newly
Rare genetic diseases – what’s in store for 2021?
Working together against COVID-19
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
In the past year, we have seen partnerships between companies such as Pfizer and BioNTech; Oxford University and AstraZeneca and more recently GSK and CureVac. ... doi:10.1136/bmj.n129. 24. Dean G, Reuters. The UK approved Pfizer’s vaccine too quickly
-
What does the COVID-19 vaccine mean for the future of R&D?
Both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were developed using platform technologies which didn’t exist 20 years ago, allowing these vaccines to be developed much faster.
-
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so
-
Mistrust in medical research: a patient perspective
Health Products Regulatory Agency’s speedy approval of the Pfizer-BioNTech COVID-19 vaccine in the UK. ... A good example is a recent incident in the UK that made headline news, where two NHS workers who were among the first to receive the
-
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. ... At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
